Objective: To evaluate the clinical efficacy of modified Wu Mei Wan granules in children with mixed cold-heat type allergic rhinitis (AR).
Methods: A total of 54 children with mixed cold-heat type AR, treated at the Third Affiliated Hospital of Fujian University of Traditional Chinese Medicine from July 2023 to July 2024, were enrolled and randomly divided into two groups using a random number table. The control group (n=27) received loratadine tablets, while the observation group (n=27) was administered modified Wu Mei Wan granules. Both groups underwent treatment for 4 weeks. The clinical efficacy was compared between the two groups, and changes in the total symptom score, visual analog scale (VAS) score, immune function, and inflammatory cytokine levels were assessed before and after treatment.
Results: Compared to the control group, the overall clinical effectiveness rate in the observation group was significantly higher (p<0.05). After treatment, the total symptom scores, VAS scores, and serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels were significantly reduced in both groups (all p<0.01), with a greater reduction in IL-4 levels in the observation group compared to the control group (p<0.05). Additionally, interferon-γ (IFN-γ) levels were significantly increased in both groups (p<0.01), with a more pronounced increase in the observation group compared to the control group (p<0.05).
Conclusion: Modified Wu Mei Wan granules can improve the clinical efficacy in children with mixed cold-heat type AR. The mechanism may involve regulating the Th1/Th2 immune balance and reducing allergic reactions, which can help improve the quality of life in these children and is worthy of clinical promotion.
